Viewing Study NCT02113800

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 12:17 PM
Ignite Modification Date: 2026-02-22 @ 7:22 PM
Study NCT ID: NCT02113800
Status: COMPLETED
Last Update Posted: 2020-10-28
First Post: 2014-04-08
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
Sponsor: AIO-Studien-gGmbH
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Poorly Differentiated Malignant Neuroendocrine Carcinoma View
None Neuroendocrine Carcinoma, Grade 3 View
None Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to … View
None Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched … View
None Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by … View
Keywords: